药物性肝损伤的糖皮质激素治疗:注意空白!
约80%的特异性药物性肝损伤(DILI)在停药后缓解,但10%-15%患者肝损伤持续超过6个月,约10%在DILI发病2年内死亡,高达10%患者停药后仍可能进展为肝衰竭。糖皮质激素因其抗炎特性被用于预防DILI进展,尤其在高剂量用于检查点抑制剂诱导的肝损伤(ChILI)时,但无证据表明其加速急性肝损伤缓解或降低死亡/肝移植风险,反而可能延迟ChILI缓解并增加不良事件。
要点
- 多数DILI停药后缓解,但部分患者肝损伤持续或进展。
- 无证据表明糖皮质激素加速急性DILI缓解或降低死亡/移植风险。
- 高剂量长疗程糖皮质激素可能延迟ChILI缓解并增加不良事件。
核心结论
- 糖皮质激素治疗急性DILI缺乏获益证据,且可能带来 harm,尤其在ChILI中。
主要发现
- 约80%的特异性DILI在停药后缓解。
- 10%-15%患者肝损伤持续超过6个月。
- 约10%患者在DILI发病2年内死亡。
- 高达10%患者停药后仍可能进展为肝衰竭。
- 糖皮质激素可能延迟ChILI缓解并增加不良事件。
关键数值与推荐
- 对于ChILI,当停用检查点抑制剂后胆红素持续升高、肝组织学显示明显持续坏死性炎症且排除胆汁淤积或胆管病时,可选择性考虑中等剂量泼尼松龙并在4周内逐渐减量。
临床怎么用
- 不推荐常规使用糖皮质激素治疗急性DILI。
- ChILI患者可考虑糖皮质激素节省策略。
- 选择性使用泼尼松龙需满足特定条件并逐渐减量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiosyncratic drug-induced liver injury (DILI) resolves following discontinuation of the causative drug in about 80% of individuals. However, liver injury may persist beyond 6 months in 10%-15% of patients, and about 10% die within 2 years of DILI onset. DILI may progress to liver failure even after withdrawal of the offending medication in up to 10% of patients. Consequently, corticosteroids, because of their anti-inflammatory properties, have been used to prevent progression of DILI. With the advent of highly effective checkpoint inhibitors for the treatment of a variety of cancers, corticosteroids are increasingly used at high doses with the intention of accelerating resolution of liver injury. However, there is no evidence that corticosteroids hasten resolution of acute liver injury or reduce the risk of death or liver transplantation in acute DILI. In fact, corticosteroids can impair tissue repair and regeneration and may induce resistance, particularly when used at high doses for prolonged periods to treat checkpoint inhibitor-induced liver injury (ChILI). Indeed, their use has been associated with delayed resolution of ChILI and increased adverse effects. When used to treat immune-related adverse events within 2 months of initiating checkpoint inhibitors across a wide range of cancers, corticosteroids have even been associated with reduced overall survival. Corticosteroid-sparing approaches appear to be safe and effective in the majority of patients with ChILI. A modest dose of prednisolone, tapered over 4 weeks, may be considered selectively in patients with ChILI when bilirubin continues to rise after withdrawal of the checkpoint inhibitor, liver histology demonstrates marked ongoing necroinflammation, and cholestasis or cholangiopathy has been excluded.
引用
- Aithal GP, Weber S, Franks H, et al. Corticosteroid therapy for drug-induced liver injury: Mind the gap! J Hepatol. 2026. PMID: 42556620. doi:10.1016/j.jhep.2026.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。